secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001493152-26-014813
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals launches generic methadone tablets; addresses $22M market
-------------------------------------------------------------------------------

- Launched generic methadone HCl 5 mg and 10 mg tablets under Elite Laboratories label.
- Product indicated for severe persistent pain and opioid addiction detoxification/maintenance treatment.
- Annual retail sales for brand and generic methadone tablets approx. $22M (IQVIA 2025 data).
- Company operates a cGMP and DEA-registered R&D and manufacturing facility in Northvale, NJ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226014813/0001493152-26-014813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315226014813/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer